| Colicins and their potential in cancer treatment LE Lancaster, W Wintermeyer, MV Rodnina Blood Cells, Molecules, and Diseases 38 (1), 15-18, 2007 | 72 | 2007 |
| Identification of the catalytic motif of the microbial ribosome inactivating cytotoxin colicin E3 D Walker, L Lancaster, R James, C Kleanthous Protein Science 13 (6), 1603-1611, 2004 | 43 | 2004 |
| Colicin E3 cleavage of 16S rRNA impairs decoding and accelerates tRNA translocation on Escherichia coli ribosomes LE Lancaster, A Savelsbergh, C Kleanthous, W Wintermeyer, ... Molecular microbiology 69 (2), 390-401, 2008 | 37 | 2008 |
| Chitosan nanoparticle antigen uptake in epithelial monolayers can predict mucosal but not systemic in vivo immune response by oral delivery H Cole, D Bryan, L Lancaster, F Mawas, D Vllasaliu Carbohydrate polymers 190, 248-254, 2018 | 32 | 2018 |
| Consequences of inducing intrinsic disorder in a high-affinity protein–protein interaction G Papadakos, A Sharma, LE Lancaster, R Bowen, R Kaminska, AP Leech, ... Journal of the American Chemical Society 137 (16), 5252-5255, 2015 | 25 | 2015 |
| Mechanistic and phenotypic studies of bicarinalin, BP100 and colistin action on Acinetobacter baumannii MG Eales, E Ferrari, AD Goddard, L Lancaster, P Sanderson, C Miller Research in microbiology 169 (6), 296-302, 2018 | 20 | 2018 |
| Immunogenicity and physico-chemical characterisation of a candidate conjugate vaccine against group B streptococcus serotypes Ia, Ib and III L Lancaster, M Saydam, K Markey, MM Ho, F Mawas Vaccine 29 (17), 3213-3221, 2011 | 8 | 2011 |
| An assessment of thermal stability of Clostridium difficile toxoid formulations LE Lancaster, K Markey, MM Ho Human Vaccines 7 (2), 202-210, 2011 | 2 | 2011 |
| Defining the mode of action and inhibition of the colicin E3 ribosomal RNase LE Lancaster University of York, 2005 | 1 | 2005 |
